- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02076087
Immune Characterization of Subcutaneous Adipose Tissue (ATI)
September 6, 2017 updated by: Washington University School of Medicine
The overall goal of this proposal is to characterize the immune cell profile of subcutaneous abdominal adipose tissue in lean, overweight, obese and lipedema adults, and to evaluate potential associations between different adipose tissue immune cell types and metabolic profile.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
19
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
50 women already scheduled to undergo liposcution/lipectomy procedure for breast reconstruction associated with prophylactic mastectomy or mastectomy for in situ ductal breast corcinoma, cosmetic surgery, or abdominal lipectomy for severe obesity at either Barnes-Jewish Hospital or Barnes-Jewish West County Hospital.
Subjects of all races and ethnicity, with a body mass index (BMI) greater than or equal to 18.5 kg/m² and between the ages of 18 and 65 years of age will be included in the study.
Description
Inclusion Criteria:
- Women of all races and ethnicity
- Age between 18 and 65 years
- Body Mass Index (BMI) ≥ 18.5 kg/m²
- Weight stable (+/- 3% during the last 2 months before enrollment)
- Women already scheduled for above mentioned procedures
Exclusion Criteria:
- Diabetes Mellitus
- Recent (<5 years) history of cancer (except in situ ductal breast carcinoma)
- Chemotherapy and/or radiation therapy within 4 months before enrollment
- Immune system diseases (i.e., autoimmune disorders, acquired immunodeficiency syndrome)
- Pregnant or breastfeeding
- Take any medication that might affect immune function
- Severe organ dysfunction
- BMI <18.5 kg/m² or size of each breast is >600 grams, if scheduled for bilateral breast reconstruction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Normal Weight (BMI: 18.5-24.9 kg/m²)
Liposuction/lipectomy
|
Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
|
Overweight (BMI: 25.0-29.9 kg/m²)
Liposuction/lipectomy
|
Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
|
Obese (BMI: >30.0kg/m²)
Liposuction/lipectomy
|
Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the types of immune cells and the relative prevalence of each type and sub-type, in subcutaneous adipose tissue of normal weight, overweight, obese and lipedema adults.
Time Frame: intraoperative
|
intraoperative
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the relationships among specific types and subtypes of immune cells, adiposity and cardiometabolic risk.
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 1, 2014
Primary Completion (ACTUAL)
September 1, 2017
Study Completion (ACTUAL)
September 1, 2017
Study Registration Dates
First Submitted
February 27, 2014
First Submitted That Met QC Criteria
February 28, 2014
First Posted (ESTIMATE)
March 3, 2014
Study Record Updates
Last Update Posted (ACTUAL)
September 7, 2017
Last Update Submitted That Met QC Criteria
September 6, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2013-02113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Determine Immune Cell Types in Subcutaneous Adipose Tissue
-
Ruijin HospitalUnknownALK-negative Anaplastic Large Cell Lymphoma | Peripherial T Cell Lymphoma,Not Otherwise Specified | Angioimmunoblastic T Cell Lymphoma | Enteropathy Associated T Cell Lymphoma | Hepatosplenic T Cell Lymphoma | Subcutaneous Panniculitis Like T Cell LymphomaChina
-
Shandong Provincial HospitalUnknownHepatosplenic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ALK-negative Anaplastic Large Cell Lymphoma | Angioimmunoblastic T Cell Lymphoma | Enteropathy Associated T Cell Lymphoma | Subcutaneous Panniculitis Like T Cell LymphomaChina
-
National Cancer Institute (NCI)CompletedSubcutaneous Panniculitis-Like T-Cell Lymphoma | T-Cell Peripheral Lymphoma | Gamma Delta Hepatosplenic T-Cell Lymphoma | NK T-Cell LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.WithdrawnBrentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaRecurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated T-Cell Lymphoma | Recurrent Follicular T-Cell Lymphoma | Recurrent Hepatosplenic T-Cell Lymphoma | Recurrent... and other conditionsUnited States
-
University of PennsylvaniaParker Institute for Cancer Immunotherapy; Tmunity TherapeuticsTerminatedMelanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial SarcomaUnited States
-
Centre Hospitalier Universitaire VaudoisActive, not recruitingMetastatic Melanoma Naive to Immune Therapy in Metastatic SettingSwitzerland
-
Novartis PharmaceuticalsTerminatedIn Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung CancerUnited States, Italy, Taiwan, Belgium, Spain, Germany, Japan
-
Novartis PharmaceuticalsCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingOsteosarcoma | Lymphoblastic Lymphoma | Recurrent Lymphoma | Recurrent Malignant Neoplasm | Hodgkin Lymphoma in Remission | Leukemia in Remission | Recurrent LeukemiaUnited States, Australia, Canada, Puerto Rico
-
CENTOGENE GmbH RostockTerminatedLymphangioleiomyomatosis | Subependymal Giant Cell Astrocytoma | Facial Angiofibroma | Cortical Dysplasia | Renal Angiomyolipoma | Hypomelanotic Macules | Shagreen Patches | Ungual Fibromas | Cardiac RhabdomyomaSri Lanka, Albania, Romania, Egypt, Pakistan, Georgia, India, Lithuania
Clinical Trials on Liposuction/lipectomy
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
AntriaCompletedSoft Tissue Mass RemovalUnited States
-
Assiut UniversityUnknown
-
University of AarhusCompletedMesenchymal Stem Cells
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado...CompletedDisproportionate Shape | Expanded Fat PadsUnited States
-
Cairo UniversityUnknown
-
Sohag UniversityActive, not recruiting
-
Tampere University HospitalCompletedSubcutaneous Abdominal Fat | Abdominal Skin Elasticity | Rectus Muscle Diastasis | Unpleasant Body Contour
-
Shanghai Jiao Tong University School of MedicineCompletedMenstrual Irregularity
-
Haraldsplass Deaconess HospitalUniversity Hospital of North Norway; University of Bergen; St. Olavs Hospital; Sykehuset... and other collaboratorsRecruiting